NCT02181699View on ClinicalTrials.gov

Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

PHASE1TerminatedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

May 10, 2019

Study Completion Date

May 10, 2019

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

KHK2823

single agent KHK2823

Trial Locations (7)

BN2 5BE

University of Sussex, Royal Sussex County Hospital, Brighton

Unknown

Beatson West of Scotland Cancer Centre, Glasgow

St James's Institute of Oncology, Leeds

NIHR/Wellcome UCLH Clinical Research Facility University College Hospital London, London

St Bartholomew's Hospital, London

Northern Centre for Cancer Care, Freeman Road Hospital, Newcastle upon Tyne

Southampton General Hospital, Southampton

Sponsors

Lead Sponsor

Kyowa Kirin, Inc.
All Listed Sponsors
lead

Kyowa Kirin, Inc.

INDUSTRY